Engaging with patients and care partners benefits the drug development lifecycle by avoiding protocol amendments and increasing recruitment, adherence and retention in clinical trials. However, there are unique challenges to building and sustaining a patient engagement framework in biopharma organizations without slowing down its efforts.
In this white paper, VOZ Advisors outlines the journey of the mid-size biopharma company Incyte in committing to and integrating such a framework, pulling out the key challenges and learnings of the process, as well as a forward-looking vision.
Click this text to read the full white paper.
Sponsored by
